-+ 0.00%
-+ 0.00%
-+ 0.00%

Estrella Immunopharma activates Oregon Health & Science University site for STARLIGHT-1 EB103 lymphoma trial

PUBT·08/03/2026 12:02:49
Listen to the news
Estrella Immunopharma activates Oregon Health & Science University site for STARLIGHT-1 EB103 lymphoma trial
  • Estrella Immunopharma opened Oregon Health & Science University as a third U.S. site for its Phase I/II STARLIGHT-1 trial of EB103 in relapsed or refractory B-cell non-Hodgkin’s lymphoma.
  • The new site has begun screening patients, supporting broader enrollment as the study moves through its expansion phase.
  • No clinical results have been presented; data from the expansion cohort are expected to guide the pivotal trial strategy.
  • The study aims to further assess EB103’s safety profile and signs of clinical benefit at the recommended Phase II dose.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608030800BIZWIRE_USPR_____20260803_BW077462) on August 03, 2026, and is solely responsible for the information contained therein.